Paul Stewart British endocrinologist
Stewart, Paul M. (Paul Michael), 1959-
Stewart, Paul M. 1959-
Stewart, Paul Michael 1959-....
Stewart, Paul M.
Stewart, Paul M., 19..-....
VIAF ID: 51912692 (Personal)
Permalink: http://viaf.org/viaf/51912692
Preferred Forms
- 100 0 _ ‡a Paul Stewart ‡c British endocrinologist
- 200 _ | ‡a Stewart ‡b Paul Michael ‡f 1959-....
-
-
- 100 1 _ ‡a Stewart, Paul M. ‡d 1959-
- 100 1 _ ‡a Stewart, Paul M. ‡q (Paul Michael), ‡d 1959-
-
-
- 100 1 _ ‡a Stewart, Paul M., ‡d 19..-....
- 100 1 _ ‡a Stewart, Paul Michael ‡d 1959-...
4xx's: Alternate Name Forms (11)
5xx's: Related Names (1)
Works
Title | Sources |
---|---|
Glucocorticoids and 11β-HSD1 are major regulators of intramyocellular protein metabolism | |
Glucocorticoids and bone mineral content in the childhood nephrotic syndrome | |
Hepatic 11beta-HSD1 mRNA expression in fatty liver and nonalcoholic steatohepatitis | |
High throughput LC-MS/MS method for the simultaneous analysis of multiple vitamin D analytes in serum | |
How should we rate research? | |
Human Delta4-3-oxosteroid 5beta-reductase (AKR1D1) deficiency and steroid metabolism | |
Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione | |
The hypertensiogenetic steroid 19-nor-progesterone does not influence cortisol inactivation by 11beta-hydroxysteroid dehydrogenase type 2. | |
Hypertension and the cortisol-cortisone shuttle | |
Hypoglycemia with enhanced hepatic glycogen synthesis in recombinant mice lacking hexose-6-phosphate dehydrogenase. | |
Hypopituitarism: clinical features, diagnosis, and management | |
Identification of VDR-responsive gene signatures in breast cancer cells | |
Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer. | |
Immunofluorescent visualisation of focal adhesion kinase in human skeletal muscle and its associated microvasculature. | |
Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome | |
Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria | |
Inherited forms of mineralocorticoid hypertension | |
Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial | |
Investigating hypertension in a young person | |
Is subclinical Cushing's syndrome an entity or a statistical fallout from diagnostic testing? Consensus surrounding the diagnosis is required before optimal treatment can be defined | |
Is there sufficient evidence to consider the use of 11β-hydroxysteroid dehydrogenase type 1 inhibition in children? | |
Lack of hexose-6-phosphate dehydrogenase impairs lipid mobilization from mouse adipose tissue | |
Lack of significant metabolic abnormalities in mice with liver-specific disruption of 11β-hydroxysteroid dehydrogenase type 1. | |
Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene | |
The long-term predictive accuracy of the short synacthen (corticotropin) stimulation test for assessment of the hypothalamic-pituitary-adrenal axis | |
Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly | |
Longitudinal changes in glucocorticoid metabolism are associated with later development of adverse metabolic phenotype | |
Low-dose growth hormone inhibits 11 beta-hydroxysteroid dehydrogenase type 1 but has no effect upon fat mass in patients with simple obesity | |
Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study | |
Male 11β-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease | |
MicroRNA-24 is a novel regulator of aldosterone and cortisol production in the human adrenal cortex | |
Minireview: hexose-6-phosphate dehydrogenase and redox control of 11{beta}-hydroxysteroid dehydrogenase type 1 activity | |
Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5α-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement | |
Modified-Release Hydrocortisone: Is It Time to Change Clinical Practice? | |
Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor | |
The modulation of corticosteroid metabolism by hydrocortisone therapy in patients with hypopituitarism increases tissue glucocorticoid exposure. | |
Modulation of glucocorticoid action and the treatment of type-2 diabetes | |
Mortality following pituitary radiotherapy | |
Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study | |
No evidence for hepatic conversion of dehydroepiandrosterone (DHEA) sulfate to DHEA: in vivo and in vitro studies | |
The ontogeny of 25-hydroxyvitamin D(3) 1alpha-hydroxylase expression in human placenta and decidua | |
Outcome of Cushing's disease following transsphenoidal surgery in a single center over 20 years | |
Oxford textbook of endocrinology and diabetes | |
Pegvisomant: an advance in clinical efficacy in acromegaly | |
The pituitary-adrenal axis and body composition | |
Pituitary disease, c2002: | |
Premature adrenarche: novel lessons from early onset androgen excess | |
Prereceptor regulation of glucocorticoid action by 11beta-hydroxysteroid dehydrogenase: a novel determinant of cell proliferation | |
Rationale for treatment and therapeutic options in Cushing's disease | |
Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation | |
Regulation of lipogenesis by glucocorticoids and insulin in human adipose tissue | |
Regulation--the real threat to clinical research. | |
Renal TLR4 mRNA expression correlates with inflammatory marker MCP-1 and profibrotic molecule TGF-β₁ in patients with chronic kidney disease. | |
The role of 11beta-hydroxysteroid dehydrogenase 1 in adipogenesis in thyroid-associated ophthalmopathy | |
The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease | |
Saving lives of patients with adrenal insufficiency: a pan-European initiative? | |
Selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 for patients with metabolic syndrome: is the target liver, fat, or both? | |
Serum- and glucocorticoid-regulated kinase isoform-1 and epithelial sodium channel subunits in human ocular ciliary epithelium | |
Sex steroid metabolism in human peripheral blood mononuclear cells changes with aging | |
SFRP2 Is Associated with Increased Adiposity and VEGF Expression | |
Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency | |
A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease | |
Synovial DKK1 expression is regulated by local glucocorticoid metabolism in inflammatory arthritis | |
Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes | |
Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action | |
TNFα-mediated Hsd11b1 binding of NF-κB p65 is associated with suppression of 11β-HSD1 in muscle | |
Treatment of primary aldosteronism | |
Updates in growth hormone treatment and mortality | |
Weight loss increases 11beta-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue | |
What happens to clinical training fellows? A retrospective study of the 20 years outcome of a Medical Research Council UK cohort |